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Summary
Background.— Comorbidities have an adverse inﬂuence on the outcome of patients with heart
failure (HF).
Aim.— We investigated the impact of peripheral vascular disease (PVD) on long-term mortality
in hospitalized patients with HF.
Methods.— We included prospectively consecutive patients (N = 799) hospitalized for a ﬁrst
episode of HF in all healthcare establishments within a single French department during 2000.
Patients with peripheral arterial disease and/or history of stroke were considered to have PVD.
Baseline characteristics and 5-year mortality were compared according to PVD status.
Results.— PVD was diagnosed in 172 patients (22%) and clinical coronary artery disease in
302 patients (38%). Patients with PVD were older, predominantly men, smokers, and more
often had diabetes and coronary artery disease. PVD was associated with an increased risk of
crude 5-year overall mortality (hazard ratio [HR] 1.65, 95% conﬁdence interval [CI] 1.35—2.03;
P < 0.001). After adjustment for covariates, the relationship remained signiﬁcant (HR 1.33, 95%
CI 1.08—1.65; P = 0.008). Compared with the expected survival, the 5-year survival of the PVD
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group was dramatically lower (24% versus 67%). The risk of cardiovascular death was higher for
PVD patients (HR 1.39, 95% CI 1.07—1.80; P = 0.014). PVD probably modulates the impact of
other covariates on outcome.
Conclusion.— PVD is a potent predictor of adverse outcome in patients with new-onset HF.
© 2008 Elsevier Masson SAS. All rights reserved.
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Résumé
Introduction.— Les comorbidités ont une inﬂuence péjorative sur le pronostic de l’insufﬁsance
cardiaque (IC).
Objectif.— Évaluer l’impact de la maladie vasculaire périphérique (PVD) sur la mortalité à long
terme des patients admis pour une première poussée d’IC.
Méthodes.— Sept cent quatre-vingt-dix-neuf patients consécutifs hospitalisés pour une pre-
mière poussée d’IC dans tous les établissements hospitaliers du département de la Somme
(France) pendant l’année 2000 on été prospectivement inclus. Le diagnostic de PVD a été
retenu en présence d’une maladie artérielle périphérique et/ou d’un antécédent d’accident
vasculaire cérébral. Les caractéristiques de base et la mortalité à cinq ans ont été comparées
en fonction de la présence ou l’absence d’une PVD.
Résultats.— Cent soixante-douze patients (22 %) des 799 patients inclus avaient une PVD. Les
patients du groupe PVD étaient plus âgés, plus souvent de sexe masculin, fumeurs, diabé-
tiques et coronariens. La présence d’une PVD était associée à une augmentation signiﬁcative
de la mortalité totale à cinq ans (hazard ratio [HR] 1,65, IC 95% 1,35—2,03 ; p < 0,001). Après
l’ajustement aux facteurs pronostiques classiques, la relation demeurait signiﬁcative (HR 1,33,
IC 95% 1,08—1,65 ; p = 0,008). La survie à cinq ans du groupe PVD était inférieure à celle de la
population générale du même âge et sexe (survie théorique) de la Somme (24% versus 67 %).
La mortalité cardiovasculaire à cinq ans était plus élevée en présence d’un diagnostic de PVD
(HR 1,39, IC 95% 1,07—1,80 ; p = 0,014).
Conclusion.— La PVD est un facteur prédictif puissant de mortalité à long terme dans cette
our
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bbreviations
I conﬁdence interval
F heart failure
AD peripheral arterial disease
.D. standard deviation
VD peripheral vascular disease
IA transient ischaemic attack
ackground
F represents a major health concern because of its high
revalence, poor prognosis and dramatic social and eco-
omic impact [1—3]. Over the past 15 years, several clinical
rials have investigated HF due to left ventricular sys-
olic dysfunction [4—7]. Major improvements in the medical
anagement of chronic systolic HF have been achieved
2,4—7]. Despite these advances, however, some data sug-
est that the long-term prognosis of HF remains poor
1—3].
It has been reported that comorbidities have a signiﬁcant
mpact on cardiovascular outcomes in HF patients [8—11]. A
rowing body of evidence suggests that comorbidities affect
he spontaneous evolution of HF and are also a direct cause
f death [8]. Recently, a community-wide study suggested
hat stroke and vascular disease might be related to death
n HF patients [8].
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iune première poussée d’IC.
s droits réservés.
The aim of this study was to determine the impact of PVD
n the long-term prognosis (5-year overall and cardiovascu-
ar mortality) of patients hospitalized for a ﬁrst episode of
F.
ethods
tudy population and inclusion criteria
pidémiologie et traitement de l’insufﬁsance cardiaque
ans la Somme (ETICS) [12,13] was a prospective observa-
ional study conducted in the Somme department of France.
he study was designed to establish the epidemiological
haracteristics and treatment of patients hospitalized for
ﬁrst episode of HF during 2000. Patients were followed
or 5 years. In 1999, the Somme population was 555,551.
hysicians —mainly cardiologists, but also internal physi-
ians and general practitioners representing primary care
nd referral centres in all private and public hospitals pro-
iding healthcare to the Somme community— agreed to
articipate in the study. There were 11 participating health-
are establishments: one university hospital, seven general
ospitals, two private clinics and one medium and long-stay
nit.
Consecutive patients 20 years old or above, hospital-
zed for a ﬁrst episode of HF in all these establishments
uring 2000, were enrolled prospectively. Patients liv-
ng outside the Somme department, patients hospitalized
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for subsequent episodes of HF and patients with severe
valvular heart disease requiring surgery were excluded.
The diagnosis of HF was made by the attending physi-
cian, based on history, symptoms, physical signs and
chest X-ray on admission [2]. Initially, 811 patients were
enrolled. During the index hospitalization, all medi-
cal ﬁles were reviewed by two senior cardiologists
to validate the diagnosis of HF according to Fram-
ingham criteria [14] amended by the Task Force on
Heart Failure of the European Society of Cardiology [2].
The diagnosis was not validated in 12 patients. A total
of 799 patients (410men and 389women) were ﬁnally
included.
Data collection
Clinical data, including medical history, cardiovascular risk
factors, comorbidities (chronic obstructive pulmonary dis-
ease, PAD, stroke, TIA and cancer), as well as results of
complementary investigations (laboratory tests, electrocar-
diogram, chest X-ray on admission, echocardiography and
coronary angiography) were recorded on individual case
report forms.
Patients with PAD and/or history of stroke/TIA were con-
sidered to have PVD. Clinical coronary artery disease was
assumed in patients with a history of ischaemic heart dis-
ease, recent documented history of myocardial infarction
or angina pectoris, or signiﬁcant coronary atherosclerosis
conﬁrmed by coronary angiography before the index hos-
pitalization for HF [1]. A patient was considered to have
hypertension in the presence of one of the following criteria:
high blood pressure during hospitalization (>160/95mmHg),
previous diagnosis of hypertension or normal blood pressure
with ongoing antihypertensive therapy [15]. Dyslipidaemia
and diabetes mellitus were deﬁned by the presence of the
disease in the patient’s history or during hospitalization,
or by the use of speciﬁc medication (lipid-lowering ther-
apy and insulin or oral hypoglycaemic drugs, respectively).
An estimate of the glomerular ﬁltration rate on admission
was calculated with the simpliﬁed Modiﬁcation of Diet in
Renal Disease (sMDRD) formula, including age, race, sex
and serum creatinine [16]. An estimated glomerular ﬁltra-
tion rate of less than 60mL/min for 1.73m2 was used to
deﬁne renal failure according to the National Kidney Dis-
ease Foundation Guidelines [17]. Left ventricular ejection
fraction — available for 662 patients (83%) — was measured
by echocardiography (N = 648) and/or left ventriculogra-
phy (N = 103) during hospitalization. When ejection fraction
was assessed by both methods (N = 89), a mean value was
recorded.
The endpoints were overall mortality and cardiovascular
mortality. One-year, 3-year and 5-year overall and cardio-
vascular mortality rates after admission were determined.
Sudden death was classiﬁed as cardiovascular death. The
vital status was obtained either at a consultation by the
general practitioner or the referring cardiologist or by con-
sulting the civil registry. The cause of death was ascertained
by hospital records, death certiﬁcates and autopsy records
or by contacting the patient’s physician or the referring
cardiologist. No patients were lost to follow-up at 1 year
and 3 years. Five patients (0.6%) were lost to follow-up at
5 years.
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tatistical analysis
ontinuous variables were expressed as mean± S.D. and
ere compared with Student’s t-tests. Categorical variables
ere reported as absolute numbers and frequency per-
entages and analysed with Chi-square tests. Analyses of
ortality were performed using Cox proportional hazards
odels. For multivariable analyses of mortality, we used
predeﬁned Cox proportional hazard model that included
ovariates of potential prognostic impact (age, sex, history
f hypertension, diabetes mellitus, dyslipidaemia, smoking,
hronic obstructive pulmonary disease, renal failure, can-
er, coronary artery disease and PVD). To avoid spurious
elationship, covariates were entered in the model regard-
ess of the P-value on univariate analysis. The assumption
f proportional hazards was checked using log—minus-log
urvival plots.
Overall survival curves were generated using
aplan—Meier survival estimates. Survival of patients
n the PVD and no-PVD groups was compared with the
xpected survival of persons of the same age and sex in
he Somme department. Control data were obtained from
omme life tables for 1999 provided by the French Institute
f Statistics. The relative survival was computed as the
atio of the observed to expected survival (observed num-
er of deaths/expected number of deaths in the general
opulation).
Cardiovascular death was analysed in a Cox proportional
azards multivariable model, while patients who died of
on-cardiovascular causes were censored (as non-events) at
he time of death [18,19]. Hazard ratios (HRs) and 95% CIs
or the two groups (PVD and no PVD) were estimated for
ardiovascular death. Plots of cumulative hazard functions
ere used for cardiovascular mortality. For all tests, a P-
alue less than 0.05 was considered to be signiﬁcant. All
-values are results of two-tailed tests. Statistical analy-
is was performed with SPSS 13.0 statistical software (SPSS
nc., Chicago, IL, USA). The study conforms to the principles
utlined in the Declaration of Helsinki and was approved
y local institutional review boards. Written informed con-
ent was obtained from all patients. The database was
pproved by the French Computers and Privacy Commis-
ion.
esults
aseline characteristics
VD was diagnosed in 22% of the study population (N = 172).
he frequency of stroke/TIA was 10% (N = 80). Fourteen
ercent of patients (N = 112) had PAD. Only 20 patients
ad bipolar PVD. Table 1 shows the baseline characteris-
ics of patients according to PVD status. Patients in the
VD group were older, mostly men and had signiﬁcantly
ore cardiovascular risk factors (diabetes mellitus, smok-
ng and hypertension). Clinical coronary artery disease was
ore frequent in the PVD group. Medication at discharge
n patients surviving the index hospitalization was similar
or the PVD and no-PVD groups, except for an underuse of
igoxin and a higher rate of prescription of platelet aggre-
ation inhibitors in PVD patients.
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Table 1 Baseline characteristics of the study population.
Characteristic Overall population (n = 799) PVD (n = 172) No PVD (n = 627) p
Age, years (mean± S.D.) 75± 12 78± 9 75± 12 0.002
Women 49 (389) 41 (71) 51 (318) 0.03
History of hypertension 62 (498) 69 (118) 61 (380) 0.06
Dyslipidaemia 27 (215) 30 (51) 26 (164) 0.36
Diabetes mellitus 25 (196) 32 (55) 23 (141) 0.01
Smoking 35 (283) 47 (81) 32 (202) <0.001
Family history of cardiovascular disease 9 (68) 7 (12) 9 (56) 0.42
Chronic obstructive pulmonary disease 20 (156) 22 (37) 19 (119) 0.46
Renal failure 55 (441) 61 (105) 54 (336) 0.10
Cancer 11 (85) 12 (20) 11 (65) 0.66
Clinical coronary artery disease 38 (302) 52 (90) 34 (212) <0.001
Ejection fraction ≥ 50%a 44 (294) 50 (70) 43 (224) 0.13
Treatment at dischargeb
Angiotensin-converting enzyme inhibitors 55 (401) 56 (88) 54 (313) 0.67
Beta-blockers 23 (168) 24 (37) 23 (131) 0.82
Diuretics 89 (656) 90 (142) 89 (514) 0.59
Spironolactone 25 (183) 21 (33) 26 (148) 0.24
Calcium channel blockers 19 (141) 22 (35) 18 (106) 0.27
Digoxin 25 (186) 18 (28) 27 (158) 0.02
Platelet aggregation inhibitors 37 (268) 44 (69) 34 (199) 0.03
Oral anticoagulants 26 (214) 26 (40) 30 (174) 0.26
Amiodarone 33 (243) 27 (43) 35 (200) 0.09
Statins 14 (105) 16 (25) 14 (80) 0.49
PVD: peripheral vascular disease; S.D.: standard deviation. Data are percentages (N) unless denoted otherwise.
a Patients assessed for left ventricular ejection fraction (N = 662).
b Patients alive at discharge (N = 735).
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igure 1. Survival curves for patients with heart failure according to
urvival of the age- and sex-matched general population.peripheral vascular disease status compared with the expected
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Figure 2. Relative survival at 12, 24, 36, 48 and 60months for
heart failure patients with and without peripheral vascular disease, F
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CI 1.07—1.80; p = 0.014) (Fig. 3).expressed as a percentage of the expected survival.
Prognostic impact of PVD
PVD was associated with an increased risk of crude over-
all 5-year mortality (HR 1.65, 95%CI 1.35— 2.03; p < 0.001)
(Fig. 1). The relationship remained signiﬁcant after adjust-
ment for age and sex (HR 1.42, 95% CI 1.18—1.79; p < 0.001)
(Table 2) and after adjustment for covariates of poten-
tial prognostic importance (HR 1.33, 95% CI 1.08—1.65;
p = 0.008) (Table 2). Further adjustment for ejection frac-
tion did not modify this association (HR 1.48, 95% CI
1.16—1.90; p = 0.002). The 5-year overall survival of the PVD
group was dramatically lower than the expected survival
of the age- and sex-matched general population (Fig. 1).
One-year, 3-year and 5-year relative survival rates (i.e.
observed/expected survival) in the PVD group were lower
compared with those in the no-PVD group (65% versus 79%,
49% versus 68% and 37% versus 61%, respectively) (Fig. 2).
i
d
Table 2 Predictors of 5-year overall mortality — results of Co
Variable Adjustment for age
Hazard ratio (95% C
Age ≥ 75 years 2.56 (2.08—3.14)
Female sex 0.81 (0.67—0.97)
History of hypertension 1.12 (0.92—1.35)
Dyslipidaemia 0.80 (0.64—0.99)
Diabetes mellitus 1.45 (1.18—1.79)
Smoking 1.18 (0.94—1.48)
Chronic obstructive pulmonary disease 1.22 (0.98—1.53)
Renal failure 1.41 (1.16—1.70)
Cancer 1.93 (1.50—2.48)
Clinical coronary artery disease 1.23 (1.02—1.47)
Peripheral vascular disease 1.42 (1.18—1.79)
a Covariates in the model: age, sex, history of hypertension, diabetes
disease, renal failure, cancer, clinical coronary artery disease and periigure 3. Cumulative hazard-function plots for cardiovascular
eath in patients with heart failure, according to the presence or
bsence of peripheral vascular disease.
On multivariable analysis, PVD, age equal to 75 years or
bove, coronary artery disease, diabetes mellitus, chronic
bstructive pulmonary disease, cancer and renal failure
ere independent predictors of 5-year overall mortality
Table 2). After adjustment for age, female sex was associ-
ted with better outcome. After adjustment for covariates
f prognostic importance (including age), female sex was no
onger associated with 5-year mortality. Dyslipidaemia was
ssociated with better outcome (Table 2).
Cardiovascular causes were responsible for 63% of deaths
n patients with PVD. On multivariable Cox analysis, the risk
f cardiovascular death in patients with PVD was signiﬁ-
antly higher than that in the no-PVD group (HR 1.39, 95%We further analysed the prognostic impact of covariates
n the two groups (PVD and no PVD). Coronary artery disease,
iabetes mellitus, renal failure and cancer were associated
x multivariable analyses.
and sex Multivariable analysisa
I) P Hazard ratio (95% CI) P
<0.001 2.20 (1.77—2.73) <0.001
0.02 0.88 (0.71—1.10) 0.25
0.26 1.11 (0.91—1.35) 0.30
0.04 0.71 (0.57—0.90) 0.004
<0.001 1.28 (1.03—1.58) 0.02
0.15 0.93 (0.73—1.17) 0.52
0.07 1.49 (1.18—1.88) 0.001
<0.001 1.57 (1.30—1.91) <0.001
<0.001 2.17 (1.68—2.80) <0.001
0.03 1.27 (1.05—1.54) 0.01
<0.001 1.33 (1.08—1.65) 0.008
mellitus, dyslipidaemia, smoking, chronic obstructive pulmonary
pheral vascular disease.
16 J.-M. Tartière et al.
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iigure 4. Prognostic impact of age, sex and comorbidities on 5-ye
ascular disease (adjusted for age, sex, history of hypertension, dia
isease, renal failure, cancer and coronary artery disease).
ith mortality in patients without PVD but not in patients
ith PVD (Fig. 4). Dyslipidaemia appeared to be a protective
actor only in patients without PVD. The presence of chronic
bstructive pulmonary disease was predictive of mortality
n both groups. Finally, age equal to 75 years or above pre-
icted mortality in both groups, but the association was
tronger in the no-PVD group.
iscussion
his prospective analysis shows that the presence of PVD
n patients hospitalized for the ﬁrst time for HF has a
trong inﬂuence on the course of the disease, especially in
erms of cardiovascular mortality. Moreover, PVD probably
odulates the prognostic impact of other covariates such
s age, dyslipidaemia, diabetes mellitus, chronic obstruc-
ive pulmonary disease, renal failure, cancer and coronary
rtery disease. Our results conﬁrm that, compared with
he survival of the age- and sex-matched general popula-
ion, the long-term outcome of patients hospitalized for a
rst episode of HF remains poor. PVD and other comorbidi-
ies should, therefore, be monitored carefully and managed
ppropriately in HF patients.
In this study, we used a clinical deﬁnition for PVD:
he presence of PAD and/or stroke/TIA as markers of
ascular disease. The prevalence of PAD is acknowl-
dged to be underestimated in the general population
s well as in high-risk populations [20]. Moreover, pre-
ious studies suggest that PAD or stroke/TIA are strong
[
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qerall mortality in heart failure patients with and without peripheral
s mellitus, dyslipidaemia, smoking, chronic obstructive pulmonary
redictors of adverse outcomes in different categories of
atients with cardiovascular diseases [8,21—28]. PVD can
e considered to be a global marker of an increased
egradation of the cardiovascular system. Secondary
revention strategies are crucial, as patients with pre-
ious vascular events have a high risk of recurrence
21].
In our study, PAD or stroke/TIA can be interpreted as
he ﬁrst symptoms of a generalized vascular disease. HF
ppears as a subsequent event in this elderly population with
igniﬁcant vascular history [22,29,30]. One explanation for
his hypothesis is that inﬂammation, oxidative stress and
eurohormonal activation are phenomena involved in both
rteriosclerosis and progression of HF [31—34]. Moreover,
VD is associated with an unbalanced cardiovascular cou-
ling and can be held responsible for a more severe and rapid
ardiac impairment. Arterial stiffening and increased wave
eﬂection to the heart — two main features of arterioscle-
osis — are factors that contribute to an increased cardiac
oad. Increased pulsed pressure is one of the consequences
f this degenerative vascular process. It has been demon-
trated clearly that increased pulsed pressure is related to
dverse outcomes in patients with left ventricular dysfunc-
ion [35]. Furthermore, in patients with PAD, pulsed pressure
s correlated with increased levels of natriuretic peptides
30]. Natriuretic peptides are markers of adverse outcomes
n HF [36]. Finally, PAD and stroke/TIA are associated with
isability, impaired exercise capacity and cognitive decline
n elderly patients with HF, with potential adverse conse-
uences on survival [25,37].
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In our study, the presence of PVD seemed to modulate
the effect of age, dyslipidaemia, diabetes mellitus, chronic
obstructive pulmonary disease, renal failure, cancer and
coronary artery disease on mortality. Older age, diabetes
mellitus and renal failure had prominent adverse effects
in patients without PVD. Therefore, these variables might
be involved in the incidence and progression of vascular
disease [20,38,39]. Once the vascular disease is clinically
detectable, the prognostic impact of these covariates is no
longer observed. Similar underlying causes are responsible
for both central vascular disease and PVD, although the
magnitude is probably different. The ﬁrst location of the
vascular disease drives the nature and incidence of fatal
outcomes. However, a cumulative effect — several locations
of the vascular disease — may represent a marker of general-
ized disease. Dyslipidaemia was related to better outcome
in patients without PVD. The protective effect of dyslipi-
daemia might be interpreted as a drug effect (lipid-lowering
therapy was used to deﬁne the presence of the disease).
However, some data suggest a favourable effect of normal
or high total cholesterol levels on outcome in elderly and
patients with HF [40,41]. Chronic obstructive pulmonary dis-
ease has been reported to be a marker of reduced survival
in HF patients [8]. In this study, the prognostic importance
of chronic obstructive pulmonary disease was conﬁrmed in
both groups. Finally, cancer was associated with mortality
in the no-PVD group exclusively.
Limitations
The ETICS study was a prospective study that included
hospitalized patients exclusively. The characteristics of hos-
pitalized patients and those of patients managed on an
outpatient basis are certainly different in terms of severity
of symptoms and management. Ejection fraction was deter-
mined during the initial hospitalization in 83% of patients; a
higher rate compared with in other epidemiological studies
[8]. We aimed to establish the prognostic impact of a his-
tory of PVD at the time of ﬁrst hospitalization for acute HF
on long-term mortality. As PVD was not assessed systemat-
ically, the true frequency of PAD and stroke were probably
underestimated and the diagnosis undoubtedly focused on
symptomatic patients with more severe disease. As a coro-
nary angiography was not performed systematically in this
elderly population with new-onset HF, the diagnosis of coro-
nary artery was based on clinical data. We acknowledge that
multivariable analyses in subgroups of patients with HF may
be underpowered due to the small size of the samples.
Conclusions
Patients hospitalized for a ﬁrst episode of HF have a poor
long-term prognosis. In patients with HF, comorbidities are
potent determinants of outcome and important variables
for risk stratiﬁcation. We have demonstrated that PVD is
a marker of increased 5-year overall and cardiovascular
mortality in patients with new-onset HF. PVD is likely to mod-
ulate the effect of other variables on outcome. Therefore,
tracking and management of vascular diseases and reduction
of the occurrence of cardiovascular events related to these
[17
iseases appear to be of paramount importance, together
ith adequate guideline-orientated HF treatment.
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